Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.

Diamant E, Lachmi BE, Keren A, Barnea A, Marcus H, Cohen S, David AB, Zichel R.

PLoS One. 2014 Jan 27;9(1):e87089. doi: 10.1371/journal.pone.0087089. eCollection 2014.

2.

Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.

Paran N, Lustig S, Zvi A, Erez N, Israely T, Melamed S, Politi B, Ben-Nathan D, Schneider P, Lachmi B, Israeli O, Stein D, Levin R, Olshevsky U.

Virol J. 2013 Jul 10;10:229. doi: 10.1186/1743-422X-10-229.

3.

Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Gershoni-Yahalom O, Landes S, Kleiman-Shoval S, Ben-Nathan D, Kam M, Lachmi BE, Khinich Y, Simanov M, Samina I, Eitan A, Cohen IR, Rager-Zisman B, Porgador A.

Immunology. 2010 Aug;130(4):527-35. doi: 10.1111/j.1365-2567.2010.03251.x. Epub 2010 Mar 16.

4.

Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Rosenfeld R, Marcus H, Ben-Arie E, Lachmi BE, Mechaly A, Reuveny S, Gat O, Mazor O, Ordentlich A.

PLoS One. 2009 Jul 24;4(7):e6351. doi: 10.1371/journal.pone.0006351.

5.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

6.

Can West Nile virus outbreaks be controlled?

Lustig S, Halevy M, Fuchs P, Ben-Nathan D, Lachmi BE, Kobiler D, Israeli E, Olshevsky U.

Isr Med Assoc J. 2000 Oct;2(10):733-7. Review. No abstract available.

7.

A live attenuated West Nile virus strain as a potential veterinary vaccine.

Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M, Kobiler D, Halevy M.

Viral Immunol. 2000;13(4):401-10.

PMID:
11192286
8.
9.

PCR Identification and Differentiation of Baboon Cytomegalovirus From Other Human and Nonhuman Primate Cytomegalovirus.

Hilliard J, Lachmi BE, Soza I I, Brasky K, Mirkovic R.

Mol Diagn. 1996 Sep;1(3):267-273.

PMID:
10462570
10.

Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines.

Katz D, Lehrer S, Galan O, Lachmi B, Cohen S, Inbar I, Samina I, Peleg B, Heller D, Yadin H, Chai D, Freeman E, Schupper H, Fuchs P.

Adv Exp Med Biol. 1996;397:115-25. Review. No abstract available.

PMID:
8718590
11.

Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice.

Halevy M, Akov Y, Ben-Nathan D, Kobiler D, Lachmi B, Lustig S.

Arch Virol. 1994;137(3-4):355-70.

PMID:
7944955
12.

Divergent envelope E2 alphavirus sequences spanning amino acids 297 to 352 induce in mice virus-specific protective immunity and antibodies with complement-mediated cytolytic activity.

Grosfeld H, Lustig S, Gozes Y, Velan B, Cohen S, Leitner M, Lachmi B, Katz D, Olshevski U, Shafferman A.

J Virol. 1992 Feb;66(2):1084-90.

14.

Protection by dehydroepiandrosterone in mice infected with viral encephalitis.

Ben-Nathan D, Lachmi B, Lustig S, Feuerstein G.

Arch Virol. 1991;120(3-4):263-71.

PMID:
1659799
15.

Serologically defined linear epitopes in the E2 envelope glycoprotein of Semliki Forest virus.

Ariel N, Lehrer S, Elhanaty E, Sabo T, Brodt P, Lachmi B, Katz D, Levin R, Grosfeld H, Velan B, et al.

Arch Virol. 1990;113(1-2):99-106.

PMID:
1696808
16.

Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge.

Grosfeld H, Velan B, Leitner M, Cohen S, Lustig S, Lachmi BE, Shafferman A.

J Virol. 1989 Aug;63(8):3416-22.

17.

Determination of human IgG and IgM class antibodies to West Nile virus by enzyme linked immunosorbent assay (ELISA).

Feinstein S, Akov Y, Lachmi BE, Lehrer S, Rannon L, Katz D.

J Med Virol. 1985 Sep;17(1):63-72.

PMID:
4045436
18.

Tryptic peptide mapping of the nonstructural proteins of Semliki Forest virus and their precursors.

Glanville N, Lachmi BE, Smith AE, Kääriäinen L.

Biochim Biophys Acta. 1978 May 23;518(3):497-506. No abstract available.

PMID:
656430
19.

Translation of proteins accounting for the full coding capacity of the Semliki Forest virus 42 S RNA genome.

Glanville N, Lachmi BE.

FEBS Lett. 1977 Sep 15;81(2):399-402. No abstract available.

20.

Control of protein synthesis in Semliki forest virus-infected cells.

Lachmi B, Kääriäinen L.

J Virol. 1977 Apr;22(1):142-9.

21.

Sequential translation of nonstructural proteins in cells infected with a Semliki Forest virus mutant.

Lachmi BE, Kääriäinen L.

Proc Natl Acad Sci U S A. 1976 Jun;73(6):1936-40.

22.

Transitional control in Semliki forest virus infected cells.

Käärläinen L, Lachmi BE, Glanville N.

Ann Microbiol (Paris). 1976 Jan;127A(1):197-203.

PMID:
1275398
23.
24.

Replication of Semliki Forest virus.

Kääriäinen L, Keränen S, Lachmi B, Söderlund H, Tuomi K, Ulmanen I.

Med Biol. 1975 Oct;53(5):342-51. Review.

PMID:
1107685
25.

The effect of frog virus 3 on the biological activity of various RNA viruses.

Barzilai R, Lachmi BE.

J Gen Virol. 1973 Oct;21:201-4. No abstract available.

PMID:
4357374

Supplemental Content

Loading ...
Support Center